Fundraising Fox

Amy Schulman

InvestorFounder

Managing Partner at Polaris Partners · Board director at Sequelae · Board director at Noetik · Board director at Amagma, Inc.

Mount Pleasant, South Carolina

Writes $300K – $2M checks · typically $500K

FoundedLyndra

About

Amy Schulman is a managing partner at Polaris Partners focused on healthcare companies and early stage biotech startups. She joined the firm in 2014 and co-founded the Polaris Innovation Fund in 2017, which she continues to manage. Before Polaris she held roles at Pfizer including general counsel and president of Pfizer Nutrition and Pfizer Consumer Healthcare, was a partner at DLA Piper, and began her career at Cleary Gottlieb Steen & Hamilton; she is also a Senior Lecturer at Harvard Business School and holds degrees from Wesleyan University and Yale Law School.

Contact· self-published, not guessed

Invests in

BiotechHealthtech

Board director at Sequelae

Intro paths

In turn, Amy can intro founders to Sequelae's investors below.

Board director at Noetik

Intro paths

In turn, Amy can intro founders to Noetik's investors below.

Co-founders at Noetik

JR
Jacob RinaldiExecutive Officer, Director, Promoter
RA
Ronald AlfaExecutive Officer, Director, Promoter

Board director at Amagma, Inc.

Intro paths

In turn, Amy can intro founders to Amagma, Inc.'s investors below.

Co-founders at Amagma, Inc.

TG
Tillman GerngrossExecutive Officer, Director

Experience

  1. Romulus Central SchoolTeacher2002 — 2014
  2. Seneca Falls l School DistrictKindergarten teacher1999 — 2002

Deals · 11

ByHeartBoard seat

via Polaris Partners · filed May 2026 · $95.5M raise

SequelaeBoard seat

via Polaris Partners · filed Nov 2025 · $1.5M raise

QuralisBoard seat

via Polaris Partners · filed Sep 2025 · $24.9M raise

NoetikBoard seat

via Polaris Partners · filed Aug 2024 · $40M raise

LyndraBoard seat

via Polaris Partners · filed Dec 2023 · $206.1M raise

Cardurion Pharmaceuticals, Inc.Board seat

via Polaris Partners · filed Dec 2022 · $17.5M raise

Amagma, Inc.Board seat

via Polaris Partners · filed Dec 2022 · $10M raise

FractylBoard seat

via Polaris Partners · filed Jan 2022 · $20.1M raise

Glympse BioBoard seat

via Polaris Partners · filed Dec 2021 · $18M raise

Cyclerion TherapeuticsBoard seat

via Polaris Partners · filed Aug 2020 · $24.3M raise

X4 PharmaceuticalsBoard seat

via Polaris Partners · filed May 2017 · $50.5M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Alnylam PharmaceuticalsElevance HealthKallyopeLarkspur

Sources: the firm's website · SEC Form D filings.

Colleagues at Polaris Partners

Network12

Investors connected to Amy in public investor directories — a warm-intro map.

Frequently asked questions

Who is Amy Schulman?
Amy Schulman is a managing partner at Polaris Partners focused on healthcare companies and early stage biotech startups. She joined the firm in 2014 and co-founded the Polaris Innovation Fund in 2017, which she continues to manage. Before Polaris she held roles at Pfizer including general counsel and president of Pfizer Nutrition and Pfizer Consumer Healthcare, was a partner at DLA Piper, and began her career at Cleary Gottlieb Steen & Hamilton; she is also a Senior Lecturer at Harvard Business School and holds degrees from Wesleyan University and Yale Law School.
Where does Amy Schulman work?
Amy Schulman is Founder of Lyndra and Managing Partner at Polaris Partners and Board director at Sequelae and Board director at Noetik and Board director at Amagma, Inc..
What does Amy Schulman invest in?
Amy Schulman invests in Biotech, Healthtech.
What check size does Amy Schulman write?
Amy Schulman typically writes checks of $300K – $2M.
What companies did Amy Schulman found?
Amy Schulman founded Lyndra.
What boards does Amy Schulman sit on?
Amy Schulman holds tracked board seats at Alnylam Pharmaceuticals, Amagma, Inc., ByHeart, Cardurion Pharmaceuticals, Inc., Cyclerion Therapeutics, Elevance Health, Fractyl, Glympse Bio, Kallyope, Larkspur.

Founder mafias